10-Q: Vivos Therapeutics Reports Q1 2025 Results: Revenue Declines Amid Strategic Shift

Vivos Therapeutics' Q1 2025 revenue decreased by 12% year-over-year as the company transitions its business model towards strategic alliances and acquisitions of sleep centers.

Summary

• Vivos Therapeutics reported a net loss of $3.864 million for the three months ended March 31, 2025, compared to a net loss of $3.763 million for the same period in 2024.
• Revenue decreased by 12% to $3.016 million in Q1 2025 from $3.419 million in Q1 2024, driven by a decline in service revenue.
• Product revenue increased slightly to $1.813 million from $1.674 million year-over-year.
• Service revenue decreased to $1.203 million from $1.745 million year-over-year due to a shift in sales strategy and focus toward sleep center affiliations.
• The company is transitioning from a VIP enrollment model to a strategic alliance and acquisition model, focusing on sleep specialty providers and centers.
• Vivos had $2.342 million in cash and cash equivalents as of March 31, 2025.
• The company has substantial doubt about its ability to continue as a going concern without additional financing.
• Vivos entered into an agreement to acquire The Sleep Center of Nevada for $6 million in cash, $1.5 million in restricted common stock, and $1.5 million in contingent earn-out consideration.
• The company is seeking additional financing through debt or equity securities to fund operations and the acquisition of The Sleep Center of Nevada.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positives, such as the increase in product revenue and the strategic shift towards acquisitions, the overall tone is negative due to the revenue decline, net loss, going concern uncertainty, and delays in strategic alliances.

Positives

• Product revenue increased slightly to $1.813 million from $1.674 million year-over-year.
• The company is actively pursuing strategic alliances and acquisitions, such as The Sleep Center of Nevada, to drive future growth.
• Vivos sold 3,736 oral appliance arches in Q1 2025, generating $1.8 million in product revenue, an 8% increase in revenue from the three months ended March 31, 2024.
• General and administrative expenses remained relatively constant with a decrease of less than $0.1 million or 1% to approximately $4.9 million for the three months ended March 31, 2025.

Negatives

• Overall revenue decreased by 12% year-over-year to $3.016 million.
• Service revenue decreased significantly to $1.203 million from $1.745 million year-over-year.
• Net loss for Q1 2025 was $3.864 million.
• The company has substantial doubt about its ability to continue as a going concern without additional financing.
• Gross margin decreased to 50% for the three months ended March 31, 2025, compared to 57% for the three months ended March 31, 2024 due to the decrease in service revenue.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• The strategic alliance with Rebis has experienced delays, leading to a re-evaluation of revenue expectations.
• The acquisition of The Sleep Center of Nevada is subject to several conditions and may not be completed.
• The company faces potential Nasdaq delisting if it fails to maintain minimum stockholders' equity requirements.
• The company's sales did not grow during either of our fiscal years ended 2023 or 2024, nor the first quarter of 2025 as anticipated.

Future Outlook

The company is focused on transitioning to a strategic alliance and acquisition model, particularly with sleep centers, to drive revenue growth and achieve profitability. Vivos expects future revenue from VIP enrollments to decline substantially. The company is seeking additional financing to fund operations and acquisitions.

Management Comments

• Management is reviewing all options to obtain additional financing to fund operations.
• Management expects that the new strategic marketing and distribution alliance model will positively impact revenue growth and stockholders equity in upcoming fiscal quarters.

Industry Context

The company operates in the medical technology and services industry, specifically focusing on treatments for dentofacial abnormalities and obstructive sleep apnea (OSA). The shift towards strategic alliances and acquisitions reflects a trend in the healthcare industry to consolidate and integrate services for better patient outcomes and cost efficiency.

Comparison to Industry Standards

• It is difficult to compare Vivos directly to industry standards due to its unique business model and focus on dentofacial abnormalities and OSA treatment.
• Companies like ResMed and Philips Respironics are major players in the sleep apnea market, primarily focusing on CPAP devices and related technologies.
• Vivos' approach with oral appliances and the Vivos Method offers an alternative to traditional CPAP therapy, targeting the underlying causes of OSA.
• The company's success will depend on its ability to demonstrate the clinical efficacy and cost-effectiveness of its approach compared to established treatments.

Legal Proceedings

• The company is involved in ongoing litigation with Ortho-Tain, Inc. in both the United States District Court for the District of Colorado and the United States District Court for the Northern District of Illinois.

Stakeholder Impact

• Shareholders face the risk of potential Nasdaq delisting and dilution from future equity offerings.
• Employees face uncertainty due to the company's financial challenges and strategic shift.
• Customers (dentists and patients) may experience changes in product and service offerings as the company transitions its business model.
• Suppliers and creditors face increased risk due to the company's going concern uncertainty.

Next Steps

• Secure additional financing to fund operations and the acquisition of The Sleep Center of Nevada.
• Complete the acquisition of The Sleep Center of Nevada.
• Continue to transition the business model towards strategic alliances and acquisitions.
• Address the Nasdaq listing deficiency related to minimum stockholders' equity requirements.

Key Dates

Keywords

Vivos Therapeutics, revenue, net loss, sleep apnea, strategic alliance, acquisition, financing, going concern, VIP program, oral appliances